Research programme: fibrosis and organ failure therapeutics - Biogen
Latest Information Update: 16 Jul 2016
At a glance
- Originator University of California at San Francisco
- Developer Stromedix
- Class Monoclonal antibodies
- Mechanism of Action Integrin alphaVbeta5 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Fibrosis; Multiple organ failure
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Fibrosis in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Multiple-organ-failure in USA
- 19 Nov 2010 Preclinical trials in Fibrosis in USA (unspecified route)